Emcure Pharma shares hit upper circuit as net profit zooms 63% to Rs 197 crore

Emcure Pharma reported a 63% rise in consolidated profit to Rs 197 crore during the March quarter.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Emcure Pharma share price hit the 10 percent upper circuit in Friday's trading session after the company reported a 63 percent rise in consolidated profit after tax (PAT) to Rs 197 crore during the March quarter. The Pune-headquartered firm reported a profit after tax (PAT) of Rs 121 crore on a consolidated basis a year ago.

Shares of Emcure Pharmaceuticals Ltd. rose to Rs 1,284.4 per share on the NSE, up 10 percent. The stock had opened with a gain of 3.19 percent today and shortly hit the upper circuit amid strong buying interest from the investors. The counter has been gaining for the last three days and is up over 21 percent in the period.

The profit growth was propelled by a 19.5 percent year-over-year rise in revenue from operations, which stood at Rs 2,116 crore for the quarter ended March 31, 2025. The company's EBITDA also saw a healthy increase of 25.2 percent year-over-year to Rs 390 crore, with EBITDA margins at 18.4 percent.

Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., commented on the results, stating, "Emcure delivered a very strong performance in Q4 with all our businesses segments contributing to growth."

Emcure net profit zooms 63% to Rs 197 crore in Q4FY25

Domestic formulation sales grew by 24.8 percent YoY to Rs 929 crore, primarily fueled by strong performance in its women's health and cardio therapy segments. New focus areas such as dermatology and Over-the-Counter (OTC) products also contributed to this growth.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.